Background: Despite clear clinical benefits, there is limited evidence regarding possible complications of the novel mechanical support device Impella. Aortic and mitral valve regurgitation or injury are rare but potential complications following implantation of the Impella device. Methods: To evaluate valvular complications after the Impella device implantation, we have performed a comprehensive search of literature on multiple sites on this topic. Results and Conclusion: Ten case reports and one observational retrospective study were identified, with a total number of 19 patients identified. This article aims to draw attention to potential periprocedural complications relating to the Impella, in particular iatrogenic aortic and mitral valve injuries. Moreover, we have summarized our recommendations emphasizing the need for careful management and meticulous follow-up of these patients to avoid such potentially devastating complications.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in China, is the cause of the global pandemic Coronavirus Disease 19 (Covid-19). To date, there is no widely available vaccine or treatment, hence containment strategies are currently centred around measures ameliorating human transmission via social distancing and quarantine. Due to the magnitude of the pandemic, elective operative work had ceased within cardiac surgery at our institution and strategies adapted to facilitate safe management of surgical candidates. Here, we present the case report of an asymptomatic inpatient with prolonged viral shedding on real-time polymerase chain reaction (RT-PCR) on oropharyngeal swabs who required urgent coronary artery revascularisation, and the lessons learnt from the adapted management strategy deployed for revascularisation during the COVID-19 pandemic.